PN 3006 MIDTERM EXAM CONCLUDING
REVIEW SHEET PRACTICE SOLUTION
BUNDLED FULLY VERIFIED ONE
HUNDRED PERCENT PASS GUARANTEED
⩥ hemolytic anemia.
Answer: anemia caused by the destruction of red blood cells
⩥ signs and symptoms of hemolytic anemia.
Answer: Fatigue
Pallor
Shortness of breath
Tachycardia
Chills
Jaundice
Dark urine
Enlarged spleen
⩥ universal recipient blood type.
Answer: Type AB
, ⩥ universal donor blood type.
Answer: O negative
⩥ Rh positive (Rh+).
Answer: presence of Rh antigens on the RBC membranes
⩥ Rh negative (Rh-).
Answer: absence of Rh antigens
⩥ Coumadin (warfarin).
Answer: Anticoagulant, to limit the formation of blood coagulation
factors in the liver by interfering with vitamin K
⩥ Heparin.
Answer: Anticoagulant, that increases the action of antithrombin III on
several other coagulation factors to slow new clot development
⩥ Anticoagulants: Indications.
Answer: Used to prevent clot formation in certain settings where clot
formation is likely
Myocardial infarction
Unstable angina
Atrial fibrillation
REVIEW SHEET PRACTICE SOLUTION
BUNDLED FULLY VERIFIED ONE
HUNDRED PERCENT PASS GUARANTEED
⩥ hemolytic anemia.
Answer: anemia caused by the destruction of red blood cells
⩥ signs and symptoms of hemolytic anemia.
Answer: Fatigue
Pallor
Shortness of breath
Tachycardia
Chills
Jaundice
Dark urine
Enlarged spleen
⩥ universal recipient blood type.
Answer: Type AB
, ⩥ universal donor blood type.
Answer: O negative
⩥ Rh positive (Rh+).
Answer: presence of Rh antigens on the RBC membranes
⩥ Rh negative (Rh-).
Answer: absence of Rh antigens
⩥ Coumadin (warfarin).
Answer: Anticoagulant, to limit the formation of blood coagulation
factors in the liver by interfering with vitamin K
⩥ Heparin.
Answer: Anticoagulant, that increases the action of antithrombin III on
several other coagulation factors to slow new clot development
⩥ Anticoagulants: Indications.
Answer: Used to prevent clot formation in certain settings where clot
formation is likely
Myocardial infarction
Unstable angina
Atrial fibrillation
